Radiolabelled anti-PD-L1 peptide PET/CT in predicting the efficacy of neoadjuvant immunotherapy combined with chemotherapy in resectable non-small cell lung cancer.

• Tác giả: Dan Li, Nan Li, Bing Liu, Shiwei Liu, Nan Wu, Shi Yan, Zhi Yang, Wei Zhao, Xin Zhou, Hua Zhu
• Ngôn ngữ: eng
• Ký hiệu phân loại: 373.236 Lower level
• Thông tin xuất bản: Japan : Annals of nuclear medicine , 2025
• Bộ sưu tập: NCBI
• ID: 715870

Tóm tắt

BACKGROUND: This study aimed to evaluate the predictive value of baseline PD-L1 targeted peptide METHODS: Patients with resectable NSCLC (n = 20) enrolled in this prospective study received baseline paired RESULTS: Among 20 patients, 17 patients underwent surgery, 10 achieved an MPR and 7 did not. The SUV CONCLUSION: Baseline TRIAL REGISTRATION: NCT04304066, registered 13 November 2020, https://register. CLINICALTRIALS: gov/prs/app/action/SelectProtocol?sid=S000AEI9&selectaction=Edit&uid=U000503E&ts=2&cx=-awajet .